Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert Bourla says the company is betting big on cancer breakthroughs. He also voiced a personal belief that cures for ...

Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from ...